Assess whether pediatric studies are necessary or waivable (c3ebdd)

Situation

After a CMO 483 that maps to the NDA CMC module, CMC comparability package for a site change is what RWE evidence-strategy director can touch in an RWE group proposing a post-marketing study instead of a new RCT. Pharma & Life Sciences will live with Pediatric studies are necessary versus Waivable on this Pharmacovigilance file.

Decision

RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT must choose Pediatric studies are necessary / Waivable using CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• RWE evidence-strategy director can defend Pediatric studies are necessary from CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module in a Pharma & Life Sciences challenge.
• RWE evidence-strategy director cannot defend Pediatric studies are necessary from CMC comparability package for a site change; Waivable is what the extract actually supports after a CMO 483 that maps to the NDA CMC module.
• A CMO 483 that maps to the NDA CMC module never reached the population in CMC comparability package for a site change — reopen intake, do not close pediatric studies are necessary.
• Two facts in CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module conflict for RWE evidence-strategy director; hold this Pharmacovigilance file.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• For this Pharma & Life Sciences Pharmacovigilance file, read CMC comparability package for a site change against a CMO 483 that maps to the NDA CMC module and write the one fact that would move pediatric studies are necessary for RWE evidence-strategy director.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / Pharmacovigilance packet (CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module). The follow-on Pharmacovigilance action is what RWE evidence-strategy director does next: implement the option, assign an owner, and log the missing fact.